Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

The Innovative Medicines Initiative: an engine for regulatory science

Nature Reviews Drug Discovery volume 14, pages 1–2 (2015)Cite this article

Subjects

Abstract

Since its launch in 2008, the Innovative Medicines Initiative has catalysed the formation of many consortia to address challenges in drug development and regulation. As it moves into its second phase, we highlight key outcomes so far and the lessons learned.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Acknowledgements

The opinions expressed in this article do not necessarily represent the opinions and positions of the European Commission, EFPIA, EMA or IMI.

Author information

Authors and Affiliations

  1. Innovative Medicines Initiative, Brussels, B-1060, Belgium

    Michel Goldman & Nathalie Seigneuret

  2. European Medicines Agency, 30 Churchill Place, Canary Wharf, London, E14 5EU, UK

    Hans-Georg Eichler

Authors
  1. Michel Goldman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nathalie Seigneuret
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hans-Georg Eichler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michel Goldman.

Ethics declarations

Competing interests

Michel Goldman and Nathalie Seigneuret are appointed by the Innovative Medicines Initiative (IMI). Hans-Georg Eichler is a member of the IMI Scientific Committee and is appointed by the European Medicines Agency, which is a partner of some IMI consortia.

Related links

Related links

FURTHER INFORMATION

SAFE-T

eTOX

U-BIOPRED

PROactive

PROTECT

Eu2P

ADVANCE

GetReal

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goldman, M., Seigneuret, N. & Eichler, HG. The Innovative Medicines Initiative: an engine for regulatory science. Nat Rev Drug Discov 14, 1–2 (2015). https://doi.org/10.1038/nrd4520

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4520

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research